Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Total Valuation

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. carries a market capitalization of 903.24M, placing it among publicly traded companies globally. Its enterprise value stands at 5.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. currently has 1.04B shares outstanding.

Valuation Ratios

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. trades at a trailing price-to-earnings ratio of 60.32. The price-to-sales ratio is 9.07, and the price-to-book ratio stands at 6.55.

Enterprise Valuation

On an enterprise value basis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. trades at an EV/EBITDA multiple of 37.39 and an EV/FCF ratio of 99.90. The EV/Sales ratio of 7.43 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 37.39 provides insight into valuation relative to core operating earnings.

Financial Position

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. maintains a current ratio of 3.88, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.52, indicating moderate leverage, while an interest coverage ratio of 96.48 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. has paid -3.91M in income taxes, reflecting an effective tax rate of 3.91.

Stock Price Statistics

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s stock has declined approximately -12.56952% over the past 52 weeks. The 50-day moving average sits at 7.47, while the 200-day moving average is 8.29.

Income Statement

Over the trailing twelve months, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. generated 736.03M in revenue and converted that into 110.66M in net income, yielding earnings per share of 0.11. EBITDA reached 146.17M, while operating income came in at 146.17M.

Balance Sheet

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. holds 1.22B in cash and equivalents against 12.22M in total debt, resulting in a net debt position of -1.22B. Total book value stands at 1.02B, with working capital of 1.39B providing operational flexibility.

Cash Flow

After subtracting -53.14M in capital expenditures, free cash flow totaled -53.14M - equivalent to -0.05 per share.

Margins

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. operates with a gross margin of 92.06, reflecting its pricing power and cost economics. The operating margin of 19.86 and net profit margin of 15.04 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of 66.94 indicates the proportion of earnings distributed to shareholders.

Scores

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. posts an Altman Z-Score of 9.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.